ACTOS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Actos, and when can generic versions of Actos launch?
Actos is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in ACTOS is pioglitazone hydrochloride. There are twenty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the pioglitazone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Actos
A generic version of ACTOS was approved as pioglitazone hydrochloride by CHARTWELL RX on October 26th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACTOS?
- What are the global sales for ACTOS?
- What is Average Wholesale Price for ACTOS?
Summary for ACTOS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 145 |
| Patent Applications: | 2,813 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ACTOS |
| Drug Sales Revenues: | Drug sales revenues for ACTOS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ACTOS |
| What excipients (inactive ingredients) are in ACTOS? | ACTOS excipients list |
| DailyMed Link: | ACTOS at DailyMed |
US Patents and Regulatory Information for ACTOS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-003 | Jul 15, 1999 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACTOS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-003 | Jul 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACTOS
See the table below for patents covering ACTOS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 2963585 | ⤷ Sign Up | |
| Finland | 860232 | ⤷ Sign Up | |
| Cyprus | 2608 | Pharmaceutical composition for use in treatment ofdiabetes | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACTOS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0861666 | 300258 | Netherlands | ⤷ Sign Up | 300258, 20160620, EXPIRES: 20210619 |
| 1174135 | SPC026/2009 | Ireland | ⤷ Sign Up | SPC026/2009: 20101001, EXPIRES: 20210619 |
| 0861666 | C00861666/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTATIVE: BOHEST AG, CH |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
